US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Serina Therapeutics, Inc.

6.00

+0.07501.27%

Post-market: 6.000.00000.00%16:04 EDT

Volume:14.00K

Turnover:82.92K

Market Cap:59.80M

PE:-58.15

High:6.15

Open:5.79

Low:5.77

Close:5.93

Loading ...

Overview Company News Filings

LPM progresses through Bynoe lithium development activities

The Market Herald

Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach

BRIEF-Serina Therapeutics Appoints Dr. Jay Venkatesan To Its Board Of Directors

Serina Therapeutics Appoints DR. Jay Venkatesan to Its Board of Directors

THOMSON REUTERS

Stocks to Watch: Palantir Technologies, Synaptics, J&J Snack Foods, Serina Therapeutics

Serina Therapeutics's Shares Up Following $5M of Equity Financing

BRIEF-Serina Therapeutics Receives Second $5 Mln Tranche To Strengthen Cash Position

Serina Therapeutics receives funding to advance SER-252 into clinical trial

Serina Therapeutics Secures $5 Million for SER-252 Trials

Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

THOMSON REUTERS

Serina Therapeutics Inc - Funding to Advance Ser-252 Into Phase 1 Trial in H2 2025

THOMSON REUTERS

Stocks to Watch: Serina Therapeutics, Powell Max, Silexion Therapeutics

Serina Therapeutics Sells UniverXome Subsidiary

Serina Therapeutics sells UniverXome subsidiary

Serina Therapeutics Sells UniverXome Unit

MT Newswires Live

Serina Therapeutics Announces Sale of Univerxome Subsidiary

THOMSON REUTERS

Serina Therapeutics Inc - Transaction Eliminates $11.2 Million in Debt

THOMSON REUTERS

BRIEF-Serina Therapeutics Welcomes Karen J. Wilson To Its Board Of Directors

Serina Therapeutics Welcomes Karen J. Wilson to Its Board of Directors

THOMSON REUTERS

Seres Therapeutics Reports 'Positive Impact' in SER-155 Early Trial; Cash Runway Extended

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SER/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SER","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SER\",,,,,undefined,":{"symbol":"SER","market":"US","secType":"STK","nameCN":"Serina Therapeutics, Inc.","latestPrice":6,"timestamp":1749844800000,"preClose":5.925,"halted":0,"volume":14002,"hourTrading":{"tag":"盘后","latestPrice":6,"preClose":6,"latestTime":"16:04 EDT","volume":1,"amount":6,"timestamp":1749845044142},"delay":0,"floatShares":2792931,"shares":9967381,"eps":-0.103181,"marketStatus":"Market Closed","change":0.075,"latestTime":"06-13 16:00:00 EDT","open":5.79,"high":6.15,"low":5.772,"amount":82919.2448,"amplitude":0.063797,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.103181,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750060800000},"marketStatusCode":7,"adr":0,"exchange":"AMEX","adjPreClose":5.925,"preHourTrading":{"tag":"盘前","latestPrice":5.81,"preClose":5.925,"latestTime":"08:39 EDT","volume":92,"amount":534.52,"timestamp":1749818385044},"postHourTrading":{"tag":"盘后","latestPrice":6,"preClose":6,"latestTime":"16:04 EDT","volume":1,"amount":6,"timestamp":1749845044142},"volumeRatio":0.461205},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SER\",,,,,undefined,":{"symbol":"SER","floatShares":2792931,"roa":"-135.82%","roe":"-485.36%","lyrEps":-1.513928,"volumeRatio":0.461205,"shares":9967381,"dividePrice":0,"high":6.15,"amplitude":0.063797,"preClose":5.925,"low":5.772,"week52Low":3.81,"pbRate":"35.16","psRate":"1172.63","week52High":14.57,"institutionHeld":0,"latestPrice":6,"eps":-0.103181,"divideRate":0,"volume":14002,"delay":0,"ttmEps":-0.103181,"open":5.79,"prevYearClose":5.01,"prevWeekClose":5.95,"prevMonthClose":6,"prevQuarterClose":5.67,"fiveDayClose":5.95,"twentyDayClose":5.64,"sixtyDayClose":4.43},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SER\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2518763608","title":"LPM progresses through Bynoe lithium development activities","url":"https://stock-news.laohu8.com/highlight/detail?id=2518763608","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518763608?lang=en_us&edition=fundamental","pubTime":"2025-03-11 13:57","pubTimestamp":1741672620,"startTime":"0","endTime":"0","summary":"Lithium Plus Minerals Ltd  has ticked off a suite of development activities at its 4.09 million-tonne Bynoe Lithium Project in the Northern Territory, including metallurgical testing, planning for its mine and crucial infrastructure, and discussions about offtake.The project – located close to Darwin – is built around the Lei deposit, which carries a mineral resource estimate  of 4.09 million tonnes at 1.43% Li2O , numbers which LPM believes put it among the top deposits for this commodity in Australia.Development activity also sought to boost and define the quality of the resource. This included a 51% uplift in head-grade  at 57.8% mass yield for 87% lithia recovery – achieved through ore sorting trails – which allowed for the reduction of about 42% of low-grade material into a waste stream.LPM has also conducted metallurgical test work on the ore, achieving 85.3% recovery to a concentrate of 6.12% Li2O from DMS and fines and middlings flotation on a high-grade sample.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/lpm-progresses-through-bynoe-lithium-development-activities-2025-03-11/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7145","MRE.AU","LPM.AU","SER.AU","BK7507","TIA.AU","BK4139","BK7509","BK7504","BK7095","PLS.AU","SER"],"gpt_icon":0},{"id":"2516687257","title":"Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach","url":"https://stock-news.laohu8.com/highlight/detail?id=2516687257","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516687257?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:00","pubTimestamp":1741003200,"startTime":"0","endTime":"0","summary":"FDA has provided input on key elements of the SER-155 allo-HSCT clinical development plans including support for the proposed primary efficacy endpoint of reduction in bloodstream infections  as of 30 days post HSCT in the next study. Seres has submitted clarification questions to FDA and expects a response in the coming weeks, which will inform the proposed protocol for the next SER-155 study in allo-HSCT, which the Company anticipates submitting to FDA in Q2. About SER-155SER-155 is an investigational, oral, live biotherapeutic designed to decolonize GI pathogens, improve epithelial barrier integrity, and induce immune tolerance to prevent bacterial bloodstream and antimicrobial resistant  infections, as well as other patho","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/seres-therapeutics-receives-feedback-fda-120000783.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HSCT","BK4139","MCRB","BK4585","BK4006","BK4588","AMR","SER"],"gpt_icon":0},{"id":"2511046539","title":"BRIEF-Serina Therapeutics Appoints Dr. Jay Venkatesan To Its Board Of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2511046539","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511046539?lang=en_us&edition=fundamental","pubTime":"2025-02-13 06:49","pubTimestamp":1739400588,"startTime":"0","endTime":"0","summary":"BRIEF-Serina Therapeutics Appoints Dr. Jay Venkatesan To Its Board Of DirectorsSerina Therapeutics Inc SER.A:SERINA THERAPEUTICS APPOINTS DR. JAY VENKATESAN TO ITS BOARD OF DIRECTORSSource text: ID:nGNX9m5B6xFurther company coverage: SER.A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250212:nTUA4SQB2D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2511681580","title":"Serina Therapeutics Appoints DR. Jay Venkatesan to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2511681580","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511681580?lang=en_us&edition=fundamental","pubTime":"2025-02-13 05:15","pubTimestamp":1739394900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250212:nTUA4SQB2D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2508517236","title":"Stocks to Watch: Palantir Technologies, Synaptics, J&J Snack Foods, Serina Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2508517236","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508517236?lang=en_us&edition=fundamental","pubTime":"2025-02-04 07:32","pubTimestamp":1738625520,"startTime":"0","endTime":"0","summary":"Palantir Technologies blew past Wall Street's expectations for the fourth quarter as demand for its artificial-intelligence products continued to expand. The software company notched revenue of $828 million, up 36% from last year and ahead of the $776 million that analysts polled by FactSet were expecting. The beat was driven by momentum in the company's U.S. business, which grew 52% year-over-year. For 2025, Palantir forecast revenue of $3.741 billion to $3.757 billion, above the $3.503 billion that analysts had modeled. Shares jump 22%, to $102.40, in after-hours trading.Synaptics Chief Executive Michael Hurlston stepped down from the company's top role to become chief executive and president of Lumentum. Hurlston left the artificial-intelligence company to start as head of Lumentum on Friday, according to Lumentum, which makes products for cloud and AI applications. Synaptics' board launched a search for a new top executive and said Ken Rizvi, its chief financial officer, will step ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SER","SYNA","LU0012050646.USD","LU1815336760.USD","LU0106261612.USD","BK4023","LU0444971666.USD","BK4141","LU0205193047.USD","LENZ","LU1861558580.USD","LITE","LU0289961442.SGD","LU0240878834.USD","LU0511384066.AUD","BK4020","BK4547","BK4585","LU1642822529.SGD","PLTR","BK4139","LU0957808578.USD","LU0240877869.USD","LU1861559042.SGD","BK4233","BK4528","BK4205","LU2065732104.USD","UK","BK4212","LU0205194284.USD","BK4543","JJSF","BK4512","LU0289739343.SGD","BK4588"],"gpt_icon":1},{"id":"2508171411","title":"Serina Therapeutics's Shares Up Following $5M of Equity Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2508171411","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508171411?lang=en_us&edition=fundamental","pubTime":"2025-02-04 06:59","pubTimestamp":1738623540,"startTime":"0","endTime":"0","summary":"Shares of Serina Therapeutics advanced in the after-hours market after the company said it closed on a $5 million tranche of equity financing.The stock rose 6.5% to $5.23 post-market, adding to the 4.4% gain seen in regular session that saw shares close at $4.91.The company said it successfully closed the second tranche of a total $10 million equity financing agreement with strategic shareholder JuvVentures .Serina said the proceeds will be used to continue advancing its SER-252, or POZ-apomorphine, into a Phase 1 clinical trial in advanced Parkinson's disease patients in the second half of this year.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4215","BK4205","BK4588","EQR","BK4528","BK4233","SER","UK","BK4585","BK4139"],"gpt_icon":0},{"id":"2508544179","title":"BRIEF-Serina Therapeutics Receives Second $5 Mln Tranche To Strengthen Cash Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2508544179","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508544179?lang=en_us&edition=fundamental","pubTime":"2025-02-04 06:31","pubTimestamp":1738621872,"startTime":"0","endTime":"0","summary":"BRIEF-Serina Therapeutics Receives Second $5 Mln Tranche To Strengthen Cash PositionFeb 3 (Reuters) - Serina Therapeutics Inc SER.A:SERINA THERAPEUTICS RECEIVES SECOND $5 MILLION TRANCHE TO STRENGTHEN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nTUA8SDJR3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SER","BK4139"],"gpt_icon":0},{"id":"2508175659","title":"Serina Therapeutics receives funding to advance SER-252 into clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2508175659","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508175659?lang=en_us&edition=fundamental","pubTime":"2025-02-04 05:45","pubTimestamp":1738619117,"startTime":"0","endTime":"0","summary":"Serina Therapeutics (SER) announced the closing of the second $5M tranche of its previously announced $10M equity financing with strategic sharehol...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/serina-therapeutics-receives-funding-to-advance-ser-252-into-clinical-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/serina-therapeutics-receives-funding-to-advance-ser-252-into-clinical-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2508175507","title":"Serina Therapeutics Secures $5 Million for SER-252 Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2508175507","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508175507?lang=en_us&edition=fundamental","pubTime":"2025-02-04 05:35","pubTimestamp":1738618513,"startTime":"0","endTime":"0","summary":"Serina Therapeutics ( ($SER) ) has provided an update. On February 3, 2025, Serina Therapeutics announced the completion of a second $5 million tra...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/serina-therapeutics-secures-5-million-for-ser-252-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/serina-therapeutics-secures-5-million-for-ser-252-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2508971173","title":"Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2508971173","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508971173?lang=en_us&edition=fundamental","pubTime":"2025-02-04 05:30","pubTimestamp":1738618200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nTUA8SDJR3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2508173187","title":"Serina Therapeutics Inc - Funding to Advance Ser-252 Into Phase 1 Trial in H2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2508173187","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508173187?lang=en_us&edition=fundamental","pubTime":"2025-02-04 05:30","pubTimestamp":1738618200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nTUA8SDJR3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SER","BK4139"],"gpt_icon":0},{"id":"2503601701","title":"Stocks to Watch: Serina Therapeutics, Powell Max, Silexion Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2503601701","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503601701?lang=en_us&edition=fundamental","pubTime":"2025-01-16 07:45","pubTimestamp":1736984700,"startTime":"0","endTime":"0","summary":"Serina Therapeutics sold its UniverXome subsidiary in a deal finalized on Dec. 23. The biotechnology company said the transaction eliminated $11.2 million in associated subsidiary-level debt, allowing it to enter 2025 with a debt-free balance sheet. Chief Executive Steve Ledger added that the deal will allow Serina to continue advancing SER-252, its lead candidate for advanced Parkinson's disease, into clinical development. Shares jump 21%, to $5.84, in postmarket trading.Powell Max said it has commenced activities to pursue acquisitions as part of its business strategy. The company is evaluating other financial communications service providers, planning to acquire companies generating $1.5 million to $5 million in gross annual revenue. It intends to retain most of the management teams of any acquired companies. Shares surge 84%, to $2.54, in after-hours trading.Silexion Therapeutics released what the company called promising preclinical data for its treatment of pancreatic cancer. The","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SER","US30Y.BOND","US10Y.BOND","LENZ","PMAX","US5Y.BOND","BK4585","US3Y.BOND","SLXN","BK4096","GPRO","BK4139","US2Y.BOND","BK4078","US7Y.BOND","BK4112","US6M.BOND","BK4588","US12M.BOND"],"gpt_icon":1},{"id":"2503928670","title":"Serina Therapeutics Sells UniverXome Subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2503928670","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503928670?lang=en_us&edition=fundamental","pubTime":"2025-01-16 05:33","pubTimestamp":1736976780,"startTime":"0","endTime":"0","summary":"Serina Therapeutics on Wednesday said it has sold its UniverXome subsidiary in a deal which was finalized on Dec. 23.The biotechnology company said on Wednesday that the transaction eliminated $11.2 million in associated subsidiary-level debt, allowing the company to enter 2025 with a debt-free balance sheet.Chief Executive Officer Steve Ledger said the deal allows Serina to continue its focus on advancing SER-252, its lead candidate for advanced Parkinson's disease, into clinical development. The deal also allows the company to further explore the potential of its POZ platform, a technology designed to provide greater control in drug loading and the rate of release of drugs delivered via subcutaneous injection, Ledger said.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SER","LENZ","BK4139"],"gpt_icon":0},{"id":"2503670490","title":"Serina Therapeutics sells UniverXome subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2503670490","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503670490?lang=en_us&edition=fundamental","pubTime":"2025-01-16 05:25","pubTimestamp":1736976334,"startTime":"0","endTime":"0","summary":"Serina Therapeutics (SER) announced the sale of its UniverXome subsidiary. The transaction was finalized on December 23, 2024 and eliminated $11.2M...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/serina-therapeutics-sells-univerxome-subsidiary?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/serina-therapeutics-sells-univerxome-subsidiary?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","SER"],"gpt_icon":0},{"id":"2503770966","title":"Serina Therapeutics Sells UniverXome Unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2503770966","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503770966?lang=en_us&edition=fundamental","pubTime":"2025-01-16 05:20","pubTimestamp":1736976041,"startTime":"0","endTime":"0","summary":"Serina Therapeutics  said Wednesday it sold its UniverXome subsidiary.The deal, which was finalized on Dec. 23, cut $11.2 million in associated subsidiary-level debt, Serina said, adding it now has a debt-free balance sheet.The unit was set up before Serina's reverse merger with AgeX Therapeutics in March 2024 to hold the legacy assets of the predecessor company, Serina said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SER.AU","LENZ","BK4139","BK7095","SER"],"gpt_icon":0},{"id":"2503773736","title":"Serina Therapeutics Announces Sale of Univerxome Subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2503773736","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503773736?lang=en_us&edition=fundamental","pubTime":"2025-01-16 05:05","pubTimestamp":1736975100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250115:nTUA8BPQTD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SER","BK4139"],"gpt_icon":0},{"id":"2503677378","title":"Serina Therapeutics Inc - Transaction Eliminates $11.2 Million in Debt","url":"https://stock-news.laohu8.com/highlight/detail?id=2503677378","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503677378?lang=en_us&edition=fundamental","pubTime":"2025-01-16 05:05","pubTimestamp":1736975100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250115:nTUA8BPQTD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SER","BK4139"],"gpt_icon":0},{"id":"2503768012","title":"BRIEF-Serina Therapeutics Welcomes Karen J. Wilson To Its Board Of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2503768012","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503768012?lang=en_us&edition=fundamental","pubTime":"2025-01-15 06:26","pubTimestamp":1736893600,"startTime":"0","endTime":"0","summary":"BRIEF-Serina Therapeutics Welcomes Karen J. Wilson To Its Board Of DirectorsJan 14 (Reuters) - Serina Therapeutics SER.A:SERINA THERAPEUTICS WELCOMES KAREN J. WILSON TO ITS BOARD OF DIRECTORSSource text: ID:nGNX3GJmS1Further company coverage: SER.A ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250114:nTUA5KCWH0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SER","BK4139"],"gpt_icon":0},{"id":"2503680488","title":"Serina Therapeutics Welcomes Karen J. Wilson to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2503680488","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503680488?lang=en_us&edition=fundamental","pubTime":"2025-01-15 06:25","pubTimestamp":1736893500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250114:nTUA5KCWH0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2502047235","title":"Seres Therapeutics Reports 'Positive Impact' in SER-155 Early Trial; Cash Runway Extended","url":"https://stock-news.laohu8.com/highlight/detail?id=2502047235","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502047235?lang=en_us&edition=fundamental","pubTime":"2025-01-10 01:33","pubTimestamp":1736443981,"startTime":"0","endTime":"0","summary":"Seres Therapeutics  said results from a phase 1b trial of SER-155 in people undergoing allogenic stem cell transplantation showed a \"positive impact on biomarkers of systemic inflammation and immune homeostasis\" compared with placebo.The results back previous data showing that SER-155 \"was associated with a significant reduction in bloodstream infections,\" the company said Thursday in a statement.SER-155 is a live biotherapeutic designed to prevent infections in people undergoing allogenic stem cell transplantation to treat blood cancers, Seres said.The company also said its cash runway was extended into Q1 2026.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SER","MCRB","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":47,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SER\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-24","symbol":"SER","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742788800000,"reportTimeType":"post","actualEps":-0.27},{"market":"US","date":"2024-11-12","symbol":"SER","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"post","actualEps":0.13},{"market":"US","date":"2024-08-09","symbol":"SER","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723176000000,"reportTimeType":"post","actualEps":0.51},{"market":"US","date":"2024-05-14","symbol":"SER","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715659200000,"reportTimeType":"post","actualEps":-3.38},{"market":"US","date":"2024-03-22","symbol":"SER","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1711080000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SER\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SER\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1741665600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SER\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SER","date":"2025-06-12","current":-65.600015,"percent":0,"low":-65.600015,"twenty":-10.724314,"median":-6.447357,"eighty":-4.752771,"high":37.356482,"avg":-8.707113,"sd":18.352794,"marketCap":61598414},"quantilePoints":[{"date":"2024-04-05","current":29.141387,"twenty":30.584579,"median":32.083279,"eighty":33.732959,"marketCap":105541506},{"date":"2024-04-12","current":17.770243,"twenty":17.783016,"median":23.543628,"eighty":32.232039,"marketCap":93646584},{"date":"2024-04-19","current":17.456349,"twenty":17.731924,"median":17.945869,"eighty":31.172957,"marketCap":91992413},{"date":"2024-04-26","current":14.673941,"twenty":16.787882,"median":17.778226,"eighty":29.502185,"marketCap":77329529},{"date":"2024-05-03","current":14.209648,"twenty":14.673941,"median":17.57865,"eighty":21.283439,"marketCap":74882770},{"date":"2024-05-10","current":14.050147,"twenty":14.209648,"median":17.078432,"eighty":18.800885,"marketCap":74042223},{"date":"2024-05-17","current":12.820759,"twenty":14.187327,"median":15.966076,"eighty":18.090969,"marketCap":67563528},{"date":"2024-05-24","current":15.167772,"twenty":14.187327,"median":15.718602,"eighty":17.818141,"marketCap":79931945},{"date":"2024-05-31","current":-13.721878,"twenty":13.545619,"median":15.079879,"eighty":17.786209,"marketCap":79931945},{"date":"2024-06-07","current":-14.08298,"twenty":12.926135,"median":14.744671,"eighty":17.776629,"marketCap":82035417},{"date":"2024-06-14","current":-14.564515,"twenty":-13.557216,"median":14.673941,"eighty":17.770243,"marketCap":84840426},{"date":"2024-06-21","current":-15.922863,"twenty":-13.825876,"median":14.209648,"eighty":17.731924,"marketCap":92753004},{"date":"2024-06-28","current":-12.919404,"twenty":-13.944317,"median":14.209648,"eighty":17.655287,"marketCap":75257414},{"date":"2024-07-05","current":-11.364849,"twenty":-13.990538,"median":14.209648,"eighty":17.52973,"marketCap":66201907},{"date":"2024-07-12","current":-11.153551,"twenty":-13.799876,"median":13.810656,"eighty":17.339222,"marketCap":64971062},{"date":"2024-07-15","current":-13.477836,"twenty":-13.773877,"median":13.571165,"eighty":17.280659,"marketCap":78510363},{"date":"2024-08-02","current":-12.964682,"twenty":-13.747877,"median":13.539233,"eighty":17.222095,"marketCap":75521166},{"date":"2024-08-09","current":-11.364095,"twenty":-13.723872,"median":13.251843,"eighty":17.027373,"marketCap":66197511},{"date":"2024-08-16","current":-8.441425,"twenty":-13.721878,"median":2.384851,"eighty":16.171527,"marketCap":59150297},{"date":"2024-08-23","current":-10.330099,"twenty":-13.617881,"median":-8.582039,"eighty":15.966076,"marketCap":72384510},{"date":"2024-08-30","current":-10.13985,"twenty":-13.52255,"median":-9.00413,"eighty":15.966076,"marketCap":71051408},{"date":"2024-09-06","current":-10.104487,"twenty":-13.488788,"median":-9.975078,"eighty":15.85112,"marketCap":70803616},{"date":"2024-09-13","current":-7.831133,"twenty":-13.268937,"median":-9.379361,"eighty":15.707426,"marketCap":54873890},{"date":"2024-09-20","current":-7.554188,"twenty":-13.112179,"median":-8.839249,"eighty":15.365752,"marketCap":52933298},{"date":"2024-09-27","current":-9.43006,"twenty":-13.019016,"median":-9.049816,"eighty":15.0623,"marketCap":66077809},{"date":"2024-10-04","current":-8.251303,"twenty":-12.937515,"median":-8.845695,"eighty":14.905865,"marketCap":57818083},{"date":"2024-10-11","current":-8.580848,"twenty":-12.554189,"median":-8.732946,"eighty":14.786183,"marketCap":60127254},{"date":"2024-10-18","current":-9.769745,"twenty":-12.214089,"median":-8.764633,"eighty":14.702233,"marketCap":68458031},{"date":"2024-10-25","current":-8.872369,"twenty":-11.941393,"median":-8.872369,"eighty":14.673941,"marketCap":62169982},{"date":"2024-10-31","current":-8.568173,"twenty":-11.747964,"median":-8.847019,"eighty":14.628789,"marketCap":60038439},{"date":"2024-11-08","current":-5.742165,"twenty":-11.5456,"median":-8.764633,"eighty":14.420496,"marketCap":40236191},{"date":"2024-11-15","current":-6.048407,"twenty":-11.364849,"median":-8.720054,"eighty":14.209648,"marketCap":44459880},{"date":"2024-11-22","current":-5.928673,"twenty":-11.364547,"median":-8.695365,"eighty":14.209648,"marketCap":43570682},{"date":"2024-11-29","current":-6.352149,"twenty":-11.321986,"median":-8.600455,"eighty":14.209648,"marketCap":46682874},{"date":"2024-12-06","current":-7.456945,"twenty":-11.110513,"median":-8.568173,"eighty":14.187327,"marketCap":54802179},{"date":"2024-12-13","current":-6.006451,"twenty":-10.914992,"median":-8.561836,"eighty":14.088465,"marketCap":44142287},{"date":"2024-12-20","current":-7.07266,"twenty":-10.789111,"median":-8.479449,"eighty":13.954351,"marketCap":51978012},{"date":"2024-12-27","current":-6.747673,"twenty":-10.659517,"median":-8.390726,"eighty":13.571165,"marketCap":49589633},{"date":"2025-01-03","current":-6.517639,"twenty":-10.562175,"median":-8.162579,"eighty":13.520073,"marketCap":47899077},{"date":"2025-01-10","current":-5.904214,"twenty":-10.499761,"median":-8.051056,"eighty":13.363605,"marketCap":43390929},{"date":"2025-01-17","current":-6.07035,"twenty":-10.463782,"median":-7.83254,"eighty":13.258229,"marketCap":44611886},{"date":"2025-01-24","current":-6.006451,"twenty":-10.451708,"median":-7.712623,"eighty":13.14966,"marketCap":44142287},{"date":"2025-01-31","current":-5.878654,"twenty":-10.421318,"median":-7.617562,"eighty":12.926135,"marketCap":43203089},{"date":"2025-02-07","current":-5.878654,"twenty":-10.364245,"median":-7.402632,"eighty":5.571028,"marketCap":43203089},{"date":"2025-02-14","current":-5.955332,"twenty":-10.299629,"median":-7.207741,"eighty":-5.38422,"marketCap":43766608},{"date":"2025-02-21","current":-6.249265,"twenty":-10.231108,"median":-7.041606,"eighty":-5.510713,"marketCap":45926762},{"date":"2025-02-28","current":-6.380056,"twenty":-10.13985,"median":-6.713492,"eighty":-5.574659,"marketCap":46887966},{"date":"2025-03-07","current":-6.326216,"twenty":-10.13478,"median":-6.696682,"eighty":-5.743169,"marketCap":46492287},{"date":"2025-03-14","current":-5.532074,"twenty":-10.112497,"median":-6.684888,"eighty":-5.743169,"marketCap":40656021},{"date":"2025-03-21","current":-6.110856,"twenty":-10.104487,"median":-6.616553,"eighty":-5.743169,"marketCap":44909571},{"date":"2025-03-28","current":-4.234631,"twenty":-10.098885,"median":-6.511249,"eighty":-5.532216,"marketCap":47178021},{"date":"2025-04-04","current":-4.894342,"twenty":-10.073941,"median":-6.460817,"eighty":-4.926436,"marketCap":54527860},{"date":"2025-04-11","current":-4.279206,"twenty":-10.051126,"median":-6.404799,"eighty":-4.716041,"marketCap":47674632},{"date":"2025-04-17","current":-4.680381,"twenty":-10.000427,"median":-6.391338,"eighty":-4.680381,"marketCap":52144128},{"date":"2025-04-25","current":-5.429242,"twenty":-9.949728,"median":-6.352149,"eighty":-4.680381,"marketCap":60487189},{"date":"2025-05-02","current":-4.733871,"twenty":-9.769745,"median":-6.319486,"eighty":-4.680381,"marketCap":52740061},{"date":"2025-05-09","current":-5.121942,"twenty":-9.696231,"median":-6.287604,"eighty":-4.698211,"marketCap":57063554},{"date":"2025-05-16","current":-59.867974,"twenty":-10.063801,"median":-6.319486,"eighty":-4.716041,"marketCap":56216028},{"date":"2025-05-23","current":-62.521698,"twenty":-10.1145,"median":-6.352149,"eighty":-4.716041,"marketCap":58707874},{"date":"2025-05-30","current":-61.035612,"twenty":-10.269158,"median":-6.380056,"eighty":-4.730305,"marketCap":57312440},{"date":"2025-06-06","current":-63.15859,"twenty":-10.460251,"median":-6.404799,"eighty":-4.739577,"marketCap":59305916},{"date":"2025-06-12","current":-65.600015,"twenty":-10.724314,"median":-6.447357,"eighty":-4.752771,"marketCap":61598414}],"updateTime":1749880422179}}}